

Effect of therapy on residual beta cell function in type-1 diabetes mellitus

Submission date 03/10/2002	Recruitment status No longer recruiting	<input checked="" type="checkbox"/> Prospectively registered <input checked="" type="checkbox"/> Protocol
Registration date 03/10/2002	Overall study status Completed	<input type="checkbox"/> Statistical analysis plan <input type="checkbox"/> Results
Last Edited 05/09/2007	Condition category Nutritional, Metabolic, Endocrine	<input type="checkbox"/> Individual participant data <input type="checkbox"/> Record updated in last year

Plain English summary of protocol
Not provided at time of registration

Contact information

Type(s)
Scientific

Contact name
Dr Thomas Linn

Contact details
Clinical Research Unit
3rd Medical Clinic and Policlinic
Justus Liebig University
Giessen, Rodthohl 6
Germany
D-35385
+49 (0)641 99 42841
thomas.linn@innere.med.uni-giessen.de

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers
N/A

Study information

Scientific Title

Study objectives

1. Under consideration of baseline data the difference of C-peptide levels between patients under intensive therapy and conventional therapy depends on the willingness of the patients to take part in such a clinical study
2. The failure rate of intensive therapy is less than the rate of conventional therapy

Ethics approval required

Old ethics approval format

Ethics approval(s)

Not provided at time of registration

Study design

Randomised controlled trial

Primary study design

Interventional

Secondary study design

Randomised controlled trial

Study setting(s)

Not specified

Study type(s)

Treatment

Participant information sheet

Health condition(s) or problem(s) studied

Type 1 diabetes mellitus

Interventions

Conventional or intensive insulin therapy

Intervention Type

Other

Phase

Not Specified

Primary outcome measure

Not provided at time of registration

Secondary outcome measures

Not provided at time of registration

Overall study start date

01/01/2003

Completion date

01/01/2005

Eligibility

Key inclusion criteria

1. Men or women aged 18 - 40 years at diagnosis
2. Established Type-1 Diabetes diagnosed up to three months ago
3. Consent to participate in a diabetes training programme
4. Informed consent before enrolment

Participant type(s)

Patient

Age group

Not Specified

Sex

Not Specified

Target number of participants

Not provided at time of registration

Key exclusion criteria

1. History of neuropathy, nephropathy, and retinopathy of other than diabetes related origin
2. Negative C-peptide level at diagnosis
3. History of psychiatric disease or drug or alcohol abuse
4. Treatment with oral antidiabetic medication
5. Subject unlikely to comply with the protocol (e.g. inability or unwillingness to participate adequate training or to complete diaries appropriately) or to understand the nature and the scope of the study

Date of first enrolment

01/01/2003

Date of final enrolment

01/01/2005

Locations

Countries of recruitment

Germany

Study participating centre
Clinical Research Unit
Giessen, Rodthohl 6
Germany
D-35385

Sponsor information

Organisation
Justus Liebig University (Germany)

Sponsor details

-
Giessen Rodthohl 6
Germany
D-35385

Sponsor type
University/education

ROR
<https://ror.org/033eqas34>

Funder(s)

Funder type
University/education

Funder Name
Justus Liebig University (Germany)

Results and Publications

Publication and dissemination plan
Not provided at time of registration

Intention to publish date

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Protocol article	Protocol	10/12/2003		Yes	No